Altre lingue Bolt Biotherapeutics, Inc.

Azioni

BOLT

US0977021049

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,11 ^USD	-4,31%		0,00%	-0,89%

21/03	Bolt Biotherapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
21/03	Bolt Biotherapeutics, Inc. riporta i risultati degli utili per il quarto trimestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	21/03
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	27/02
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®	05/12
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu	05/12
Bolt Biotherapeutics Insider Sold Shares Worth $128,993, According to a Recent SEC Filing	01/12
Bolt Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update	09/11
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference	07/11
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress	23/10/23
Bolt Biotherapeutics : Boltbody™ISAC Platform	20/10/23
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting	18/10/23
Bolt Biotherapeutics Begins Dosing in Advanced Cancers Phase 1/2 Study of BDC-3042	17/10/23
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	17/10/23
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers	17/10/23
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	16/10/23
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023	16/10/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Bolt Biotherapeutics, Inc.

Azioni

BOLT

US0977021049

Altre lingue

Filtri